M. Grant Kels - 03 Feb 2026 Form 4 Insider Report for Veradermics, Inc (MANE)

Role
Director
Signature
/s/ Michael Greco, Attorney-in-Fact
Issuer symbol
MANE
Transactions as of
03 Feb 2026
Net transactions value
$0
Form type
4
Filing time
05 Feb 2026, 19:05:17 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Grant-Kels Jane M. Director C/O VERADERMICS, INCORPORATED, 470 JAMES ST., NEW HAVEN /s/ Michael Greco, Attorney-in-Fact 05 Feb 2026 0002108622

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MANE Common Stock Conversion of derivative security +2,455 2,455 05 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MANE Series A Convertible Preferred Stock Conversion of derivative security -2,455 -100% 0 05 Feb 2026 Common Stock 2,455 Direct F1
transaction MANE Stock Option (Right to Buy) Award $0 +51,525 $0.000000 51,525 03 Feb 2026 Common Stock 51,525 $17.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 5, 2026, the shares of Series A Convertible Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.00001 per share, on a 10.067-for-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
F2 This option shall be fully vested and exercisable on February 3, 2027, the first anniversary of the vesting commencement date.